VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis

Cell Research

Volumn 20, Issue 3, 2010, Pages 367-378

  Xiao, Tian ^a   Fan, Jun Kai ^a   Huang, Hong Ling ^a   Gu, Jin Fa ^a   Li, Lu Yuan ^b   Liu, Xin Yuan ^a,c  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Apoptosis; Oncolytic adenovirus; Tumor therapy; VEGI 251

Indexed keywords

CASPASE 3; CASPASE 9; ONCOLYTIC VIRUS; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADENOVIRUS; ANIMAL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL PROLIFERATION; GENE VECTOR; GENETICS; HELA CELL; HUMAN; METABOLISM; MITOCHONDRION; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; ONCOLYTIC VIROTHERAPY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; AUTOCRINE COMMUNICATION; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; GENETIC VECTORS; HELA CELLS; HUMANS; MICE; MICE, NUDE; MITOCHONDRIA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 77949268961     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2009.126     Document Type: Article

References (32)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996; 87:1153-1155.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
4. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-1763.
5. Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006; 12:6573-6584.
6. Zhai Y, Ni J, Jiang GW, et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 1999; 13:181-189.
7. Yu J, Tian S, Metheny-Barlow L, et al. Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 2001; 89:1161-1167.
8. Zhai Y, Yu J, Iruela-Arispe L, et al. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 1999; 82:131-136.
9. Metheny-Barlow LJ, Li LY. Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis. Semin Ophthalmol 2006; 21:49-58.
10. Chew LJ, Pan H, Yu J, et al. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 2002; 16:742-744.
11. Parr C, Gan CH, Watkins G, Jiang WG. Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 2006; 9:73-81.
12. Prehn JL, Thomas LS, Landers CJ, et al. The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 2007; 178:4033-4038.
13. Tian F, Grimaldo S, Fujita M, et al. The endothelial cellproduced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol 2007; 179:3742-3751.
14. Kakuta Y, Kinouchi Y, Negoro K, Takahashi S, Shimosegawa T. Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Gut 2006; 55:1527-1528.
15. Picornell Y, Mei L, Taylor K, et al. TNFSF15 is an ethnicspecific IBD gene. Inflamm Bowel Dis 2007; 13:1333-1338.
16. Chu L, Gu J, Sun L, et al. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Ther 2008; 15:484-494.
17. Pei Z, Chu L, Zou W, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39:1371-1381.
18. Zhang Y, Gu J, Zhao L, et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res 2006; 66:4291-4298.
19. Zhang ZL, Zou WG, Luo CX, et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003; 13:481-489.
20. Haridas V, Shrivastava A, Su J, et al. VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun Nterminal kinase and modulates cell growth. Oncogene 1999; 18:6496-6504.
21. Besnault-Mascard L, Leprince C, Auffredou MT, et al. Caspase-8 sumoylation is associated with nuclear localization. Oncogene 2005; 24:3268-3273.
22. Stennicke HR, Jurgensmeier JM, Shin H, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998; 273:27084-27090.
23. Yue TL, Ni J, Romanic AM, et al. TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stressactivated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 1999; 274:1479-1486.
24. Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16:479-492.
25. Liu XY, Qiu SB, Zou WG, et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005; 11:531-541.
26. Yang CR, Hsieh SL, Teng CM, et al. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 2004; 64:1122-1129.
27. Putzer BM, Stiewe T, Parssanedjad K, Rega S, Esche H. E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. Cell Death Differ 2000; 7:177-188.
28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
29. Zhang Z, Zou W, Wang J, et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther 2005; 11:553-562.
30. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002; 9:1022-1035.
31. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52:2745-2756.
32. Herrmann M, Lorenz HM, Voll R, et al. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 1994; 22:5506-5507.